Joel Michael Maryles - 24 May 2022 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ David S. Glatt, Esq., Attorney-in-Fact for Joel Michael Maryles
Issuer symbol
CMMB
Transactions as of
24 May 2022
Net transactions value
+$1,247
Form type
4
Filing time
25 May 2022, 16:03:50 UTC
Previous filing
21 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMMB American Depositary Shares Purchase $1,156 +400 +40% $2.89 1,400 24 May 2022 Direct F1, F2
transaction CMMB American Depositary Shares Purchase $91.08 +33 +2.4% $2.76 1,433 24 May 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,820 $0.000000 6,820 07 Mar 2022 American Depositary Shares 6,820 $3.53 Direct F1, F3, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11,884 $0.000000 11,884 19 Apr 2021 American Depositary Shares 11,884 $27.26 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2 Includes the previously reported 1,000 ADSs of the Company, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on March 21, 2022.
F3 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F4 These options vest and become exercisable in their entirety on March 16, 2023.
F5 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.